A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00361101|
Recruitment Status : Completed
First Posted : August 7, 2006
Last Update Posted : February 11, 2014
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections X4 Tropic Virus||Drug: AMD11070||Phase 1|
AMD11070 is a new chemical entity that inhibits HIV-1 entry by binding specifically and reversibly to CXCR4, a coreceptor required by T-tropic virus for membrane fusion and entry into cells. The purpose of this study is to evaluate the safety and relative antiretroviral activity of AMD11070 in HIV-infected individuals who have demonstrated X4 -tropic virus in their plasma. With the ongoing development of other fusion and entry inhibitors and the need for alternative treatment options in patients (especially those with multidrug resistant virus), the demonstration of activity and safety of AMD11070 represents a potentially important advance in antiretroviral therapeutics. This will be the first study that determines the therapeutic potential of anti-CXCR4 compounds in HIV-infected patients.
Note: Study was previously suspended due to non-clinical reports of hepatotoxicity and histologic findings. Study has been completed.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multicenter, Dose-finding Safety and Activity Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus.|
|Study Start Date :||October 2005|
|Actual Primary Completion Date :||August 2006|
|Actual Study Completion Date :||April 2010|
- Drug: AMD11070
200 mg PO BID (by mouth two times per day) for 10 days.
- safety and antiviral activity of AMD11070 administered in HIV-infected patients who harbor-X4-tropic virus. [ Time Frame: 10 days ]
- the proportion of patients per cohort who have a ≥1 log10 rlu reduction in X4-tropic virus and to describe changes from baseline to Day 10 in log10 rlu corresponding to X4-tropic virus. [ Time Frame: 10 days ]
- the relationship between standard pharmacokinetic (PK) measures, viral response, and a shift in T-cell receptor tropism. [ Time Frame: 10 days ]
- the relationship of coreceptor tropism phenotype to CD4+ count, viral load, and drug resistance in the screening patient population. [ Time Frame: 10 days ]
- the virologic activity of AMD11070 at day 10 of study treatment by analyzing the proportion of patients with Plasma HIV-1 RNA levels <400 and <50 copies/ml and the proportion with a >1 log10 decline in plasma HIV from baseline. [ Time Frame: 10 days ]
- changes in CD4+ cell counts and percentages on and off AMD11070. [ Time Frame: 10 days ]
- change from baseline in CD34+ cells [ Time Frame: 10 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00361101
|United States, Florida|
|Orlando, Florida, United States, 32803|
|London, United Kingdom, SW10 9TH|
|Study Director:||Medical Monitor||Genzyme, a Sanofi Company|